Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Tipo de estudo
Intervalo de ano de publicação
1.
SAGE Open Med Case Rep ; 8: 2050313X20970337, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33240500

RESUMO

The objective of this case series is the evaluation of the efficacy and visual outcomes after displacement of subretinal hemorrhage using intravitreal injection of recombinant tissue plasminogen activator, expansile gas, and in some cases an anti-vascular endothelial growth factor agent. A case series of 28 eyes of 28 patients (16 men and 12 women with age range 67-95 years) suffering from subretinal hemorrhage (duration range 1-15 days) caused by age-related macular degeneration or retinal macroaneurysm is presented. All the patients were treated with intravitreal injection of recombinant tissue plasminogen activator and gas and some of them received an anti-vascular endothelial growth factor agent between January 2013 and December 2016. The outcomes assessed were visual acuity (preoperatively 1 week, and 1 month postoperatively) with respect to duration and dimension of hemorrhage, displacement of hemorrhage, and possible complications of the procedure. Successful displacement of hemorrhage was achieved in 25 patients (89.3%), 18 of 28 patients had significant improvement in visual acuity 1 week after the treatment, and 22 of 28 patients had significant improvement in visual acuity 1 month after the treatment. The mean improvement of all patients with anatomical displacement of the hemorrhage in visual acuity was 0.7 ± 0.5 (LogMAR) in 1 month. Two patients developed vitreous hemorrhage after the procedure and one retinal detachment. Visual outcome a month after therapy displayed week correlation with duration, diameter, and thickness of hemorrhage. The results lead to the conclusion that intravitreal treatment of recombinant tissue plasminogen activator and expansible gas with or without injection of anti-vascular endothelial growth factor agent is effective in improving visual acuity and displacing submacular hemorrhage secondary to age-related macular degeneration and retinal macroaneurysm. The best functional outcomes can be expected in patients regardless of the size and duration of the hemorrhage.

2.
High Alt Med Biol ; 8(4): 337-9, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-18081510

RESUMO

We describe the case of a 38-year-old man who presented with bilateral retinal detachments following a trek in Tibet during which time he took acetazolamide for prophylaxis of acute mountain sickness (AMS). This is the first time that retinal detachment has been described following a sojourn to high altitude. Acetazolamide has not been previously associated with retinal detachment when used for prophylaxis of AMS or indeed during its many ophthalmic applications. The patient made a good recovery following surgery, and we speculate that, although this could be coincidental and the patient did have risk factors for retinal detachment, the possibility of a causal link to high altitude should at least be entertained. We hypothesize that vitreous dehydration may have caused vitreoretinal traction and that hypobaric hypoxia may have changed the dynamic relationship between vitreous, retina, retinal pigment epithelium (RPE) and choroid, causing preexisting retinal holes to open, allowing subretinal fluid to accumulate and detach the retina.


Assuntos
Acetazolamida/efeitos adversos , Doença da Altitude/complicações , Inibidores da Anidrase Carbônica/efeitos adversos , Montanhismo , Descolamento Retiniano/etiologia , Acetazolamida/administração & dosagem , Adulto , Altitude , Doença da Altitude/tratamento farmacológico , Inibidores da Anidrase Carbônica/administração & dosagem , Humanos , Masculino , Descolamento Retiniano/induzido quimicamente , Descolamento Retiniano/cirurgia , Tibet , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...